PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Lapatinib|DRUG: Trastuzumab|DRUG: Endocrine Therapy|DRUG: Paclitaxel
Sponsor: SOLTI Breast Cancer Research Group
Collaborators: Novartis